OptimizeRx (NASDAQ:OPRX) Given New $10.00 Price Target at Lake Street Capital

OptimizeRx (NASDAQ:OPRX) had its price objective decreased by stock analysts at Lake Street Capital from $11.00 to $10.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Lake Street Capital‘s price target points to a potential upside of 33.78% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. Citigroup reaffirmed a “market outperform” rating on shares of OptimizeRx in a research report on Tuesday, October 27th. Weiss Ratings upgraded OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, August 25th. UBS Group set a $11.00 price target on OptimizeRx in a research report on Friday, August 14th. Wall Street Zen cut OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Finally, Stifel Nicolaus dropped their price objective on OptimizeRx from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, OptimizeRx has an average rating of “Moderate Buy” and an average target price of $11.21.

OptimizeRx Trading Down 16.5%

NASDAQ OPRX traded down $1.48 during trading hours on Thursday, reaching $7.47. The company had a trading volume of 892,944 shares, compared to its average volume of 353,337. The stock has a 50-day moving average of $8.43 and a 200 day moving average of $7.24. OptimizeRx has a 1-year low of $4.54 and a 1-year high of $16.37. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $140.83 million, a P/E ratio of 32.70 and a beta of 1.20.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings results on Wednesday, November 11th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04. The business had revenue of $21.61 million during the quarter, compared to analysts’ expectations of $21.19 million. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. As a group, research analysts anticipate that OptimizeRx will post 0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OptimizeRx

A number of institutional investors have recently modified their holdings of OPRX. Royce & Associates LP lifted its stake in OptimizeRx by 20.7% in the 3rd quarter. Royce & Associates LP now owns 1,315,057 shares of the company’s stock valued at $10,981,000 after buying an additional 225,659 shares in the last quarter. Corient Private Wealth LP purchased a new stake in shares of OptimizeRx in the second quarter worth about $77,000. AWM Investment Company Inc. acquired a new stake in shares of OptimizeRx in the second quarter valued at about $1,375,000. Bank of New York Mellon Corp purchased a new stake in shares of OptimizeRx during the second quarter valued at approximately $370,000. Finally, Segall Bryant & Hamill LLC acquired a new position in shares of OptimizeRx during the first quarter worth $1,185,000. 76.47% of the stock is owned by institutional investors and hedge funds.

Top OptimizeRx Stories

Investors following OPRX have been watching these stories:

• Positive Sentiment: Q3 adjusted earnings were $0.20 per share, topping estimates of $0.16–$0.18, while revenue of about $21.6 million exceeded the roughly $21.2 million consensus. OptimizeRx Q3 2026 results and guidance
• Neutral Sentiment: B. Riley and Stifel Nicolaus maintained Buy ratings, though they lowered their price targets to $10.50 and $11, respectively—signaling continued optimism but more cautious valuation expectations. B. Riley ratings Stifel Nicolaus ratings
• Negative Sentiment: OptimizeRx forecast FY 2026 revenue of $87 million–$93 million, below the $96.2 million analyst consensus. The weaker outlook may overshadow the quarterly earnings and revenue beats. Company results and guidance

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.